Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10196373 | 0.75 | — | — | |
| SCHEMBL914589 | 0.64 | ELANE (0.37) | ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL1155690 | 0.64 | — | — | |
| SCHEMBL5367580 | 0.61 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL29649268 | 0.61 | HTT (0.41) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL1988087 | 0.61 | HTT (0.41) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL333300 | 0.60 | MAPT (0.42) | ALDH1A1SMN1; SMN2KDM4EHSD17B10KMT2A | |
| SCHEMBL9923692 | 0.60 | — | — | |
| SCHEMBL3878191 | 0.58 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL17921637 | 0.58 | PLK1 (0.39) | ALDH1A1SMN1; SMN2HTTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2335702-A1 | Product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent | IPSEN PHARMA (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFICQUES | 2009-10-08 | — | — | US | disclosed |
| EP-1641453-B1 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | IPSEN PHARMA (FR) | 2009-08-19 | — | — | EP | disclosed |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-28 | — | — | US | disclosed |
| US-20090131428-A1 | BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-21 | — | — | US | disclosed |
| US-20090082345-A1 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-03-26 | — | — | US | disclosed |
| US-7495021-B2 | Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-20070293487-A1 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS | SOCIET DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-12-20 | — | — | US | disclosed |
| US-20070255063-A1 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-11-01 | — | — | US | disclosed |
| US-7279467-B2 | Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-10-09 | — | — | US | disclosed |
| EP-1461326-B1 | BENZOTHIAZOLE- AND BENZOXAZOLE-4,7-DIONE DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATASE INHIBITORS | SOD CONSEILS RECH APPLIC (FR) | 2007-08-01 | — | — | EP | disclosed |
| EP-1792905-A1 | Product containing at least one phosphatase CDC25 inhibitor combined with at least one other anticancer agent | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2007-06-06 | — | — | EP | disclosed |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-12-14 | — | — | US | disclosed |
| EP-1641453-A2 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-04-05 | — | — | EP | disclosed |
| US-20060040996-A1 | Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2006-02-23 | — | — | US | disclosed |
| WO-2005000852-A2 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2005-01-06 | — | — | WO | disclosed |
| EP-1461326-A1 | BENZOTHIAZOLE- AND BENZOXAZOLE-4,7-DIONE DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003055868-A1 | BENZOTHIAZOLE- AND BENZOXAZOLE-4,7-DIONE DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131428-A1 | BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS | CDC25C, CDC25A, CDC25B | ALDH1A1 1054/4885SMN1; SMN2 4855/4885KDM4E 665/4885 |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | CDC25A, CDC25C, CDC25B | ALDH1A1 2847/4885SMN1; SMN2 3763/4885KDM4E 2266/4885 |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | CDC25A, CDC25C, CDC25B | ALDH1A1 2313/4885SMN1; SMN2 3760/4885KDM4E 2301/4885 |
| US-20070293487-A1 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS | CDC25C, CDC25A, CDC25B | ALDH1A1 868/4885SMN1; SMN2 4854/4885KDM4E 651/4885 |
| US-20070255063-A1 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS | CDC25A, CDC25C, CDC25B | ALDH1A1 2061/4885SMN1; SMN2 4732/4885KDM4E 576/4885 |
| US-20060040996-A1 | Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors | DUSP5, DUSP15, CDC25C | ALDH1A1 907/4885SMN1; SMN2 4860/4885KDM4E 1042/4885 |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | CDC25A, CDC25C, CDC25B | ALDH1A1 2408/4885SMN1; SMN2 3708/4885KDM4E 2096/4885 |
| US-20090082345-A1 | BENZOTHIAZOLE- AND BENZOOXAZOLE-4,7-DIONE, DERIVATIVES AND THEIR USE AS CDC25 PHOSPHATE INHIBITORS | CDC25C, CDC25A, CDC25B | ALDH1A1 868/4885SMN1; SMN2 4854/4885KDM4E 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.